HABP and VABP are extremely challenging infections to manage for various reasons. Here’s my take on how new recommendations and tools can help lead to early effective therapy.
Guidelines for hospital-acquired and ventilator-associated bacterial pneumonia are great, but you have to bring it back to the individual.
The problem with antibiograms is that they capture essentially the first specimen from a patient, and flora change with time and treatment.
Working closely with frontline ICU pharmacists and physicians is vital to obtaining microbiological histories, recent antimicrobial exposures, and drug allergies to optimize therapy on an individual level.
Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Listen to expert insights on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Hear expert insights on key concepts in HABP/VABP and Gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.